Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05034653
Other study ID # NMRR-19-3261-51726
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2020
Est. completion date May 5, 2021

Study information

Verified date September 2021
Source Ministry of Health, Malaysia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a quasi-experimental study established to determine the cardio-metabolic, anthropometric, dietary intake and quality of life changes following combined Intermittent Fasting Healthy Plate and Healthy Plate interventions among overweight and obese civil servants.


Description:

BACKGROUND Overweight and obesity among adults is a growing global public health threat and an essential risk factor for various non-communicable diseases. Although it is largely preventable, the worldwide prevalence of obesity nearly tripled from 1975 and 2016 and remained increasing each year. In 2016, more than 1.9 billion adults were overweight, and 650 million were obese. If this current trend continues, it is estimated that 2.7 billion and over 1 billion adults will be overweight and obese by 2025, respectively. Since obesity occurs due to positive energy balance in the body, the strategies of preventing and treating obesity mainly focus on dietary modification and increasing physical activity. One form of calorie restriction dietary protocol is intermittent fasting (IF), which encompasses various eating diet plans that cycle between a period of fasting and non-fasting over a defined period to create a negative energy balance, hence inducing weight loss. Studies have shown that IF is effective in reducing body weight and improving metabolic outcome. Although the effects of wet IF have been well documented, the benefits of dry IF (except for Ramadan fasting) is not clearly indicated in previous studies. Dry IF is defined as complete fasting without food and fluid intake. As portion size is a crucial determinant of energy intake, portion control by controlling the serving size is another practical method to reduce calorie intake and promote weight loss. This portion control method has been widely practised and studied worldwide, using different portion divisions depends on the culture and eating habits. Malaysia Healthy Plate, a portion control dietary plan, was created to translate the messages in Malaysia Dietary Guideline 2010 and the Malaysia Food Pyramid 2010. It is a visual tool that emphasises the quarter-quarter-half concept that provides a quick visual technique that helps ensure the intake of food is within the recommended guideline. Specifically, Malaysia Healthy Plate is a single-meal guide that divides the plate into a quarter plate of grains or grains products, a quarter plate of fish, poultry, meat or egg, and a half plate of fruits and vegetables. While weight losses are reported in studies of conventional IF, the adaptive phenomenon of dry IF on Monday and Thursday on cardiometabolic and anthropometric outcomes is still unclear. Similarly, although the policy of Malaysia Healthy Plate has been widely practised and publicised since 2010, the effectiveness of this eating plan in improving cardiometabolic risks and promoting weight loss is still not well documented. Thus, this study aimed to determine the cardiometabolic, anthropometric, dietary intake and quality of life changes among overweight and obese civil servants following combined Intermittent Fasting and Healthy Plate (IFHP) and Healthy Plate (HP), and to explore the participants' experience throughout the study. The investigators want to investigate whether combining dry IF and HP diet protocol will improve those parameters compared to HP alone. METHODS This was a mixed-method quasi-experimental study that evaluates the effectiveness of IFHP and HP among overweight and obese adults. A total of 177 participants were recruited in this study, of which 91 was allocated in the IFHP group and 86 in the HP group. The intervention comprises two phases; supervised (12 weeks) and unsupervised (12 weeks). The data collection was conducted during baseline, after the supervised phase (at week 12), and after the unsupervised phase (at week 24). For each participant, serum and whole blood were collected for analysis. Data on socio-demographic, quality of life, physical activity and dietary intake were also obtained using questionnaires during data collection. The sample size calculation was conducted using the Power and Sample Size Program. It was followed the rules required for the comparison of two groups (10). The sample size was estimated using the level of significance (α =0.05) and power of the study (1-β=0.80), minimum suggested difference (delta) of 5% weight loss that may be achieved under this intervention and the corresponding differences between groups (SD=10%). The minimum sample size required for the study is 64 participants. By considering 40% attrition, the required sample size for each arm is 90 participants. The total number of participants required for this study is 180. Data Management To ascertain that the data collection and record-keeping are conducted efficiently, the Data Collection Booklet was developed and assigned to each participant of this study. This booklet consists of five sections (Socio-demographic, Quality of Life, Physical Activity, Dietary Record and Anthropometry Measurements Sections) sorted into three parts representing each point of data collection; baseline, month three and month six. This booklet was used as a data collection tool to record responses and measurements of the participant during baseline and follow-ups. Data recorded in the booklet was then entered into a database at the end of the study. The data cleaning procedure was conducted by crosschecking all the entered data in the database and booklet and exploring the data to detect any significant outliers that possibly resulted from measurement error or data entering. Data Analysis Analysis was conducted using the Statistical Package of Social Science (SPSS) software version 25 (IBM Corp, NY). Data for continuous variables were presented by mean ± standard deviation (SD) or median and interquartile range (IQR) (for non-normally distributed data). For categorical variables, frequencies were calculated and presented together with percentages. Variables were compared using the independent t-test or Mann-Whitney U test for continuous variables and the Chi-squared or Fisher's exact (n≤5 in any cell) test for categorical variables. All statistical tests were two-sided and used a significance level of p <0.05. In further analysis, the repeated measures ANOVA will be used to compare the within and between groups changes of the outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 177
Est. completion date May 5, 2021
Est. primary completion date April 7, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 59 Years
Eligibility Inclusion Criteria: - aged 19-59 years - BMI of = 23 kg/m2 (overweight or obese) - who is ready to participate in the intervention (was assessed through readiness to participate screening) - who can provide informed consent. Exclusion Criteria: - has recent involvement in weight loss program/activity (intermittent fasting/diet changes/physical activity changes or any activities that are performed constantly to reduce weight) - suffering from any eating disorder - was diagnosed with diabetes and hypertension (on medication) or other metabolic health disturbances such as thyroid disease, chronic kidney disease, malignancy and polycystic ovarian syndrome (PCOS) - taking any medication or supplements that can affect study outcome - pregnant - has lack of capacity/language skills to independently follow the protocol were excluded from this study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Intermittent Fasting
During fasting day, no food or drink allowed from dawn to dusk
Healthy Plate
Quarter-quarter-half meal concept

Locations

Country Name City State
Malaysia Institut Latihan Kementerian Kesihatan Malaysia Kuala Lumpur
Malaysia Institute for Medical Research Kuala Lumpur
Malaysia National Institute of Health Shah Alam Selangor

Sponsors (1)

Lead Sponsor Collaborator
Ministry of Health, Malaysia

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body weight changes Body weight changes measured in kilogram Change from Baseline Body Weight at week 12
Primary Body weight changes Body weight changes measured in kilogram Change from Baseline Body Weight at week 24
Primary Body mass index (BMI) changes Body mass index changes measured in kg/m^2 (weight in kilograms, height in meters) Change from Baseline BMI at week 12
Primary Body mass index (BMI) changes Body mass index changes measured in kg/m^2 (weight in kilograms, height in meters) Change from Baseline BMI at week 24
Primary Waist-Hip Ratio (WHR) changes WHR changes measured in centimeters (waist and hip circumference in centimeters) Change from Baseline WHR at week 12
Primary Waist-Hip Ratio (WHR) changes WHR changes measured in centimeters (waist and hip circumference in centimeters) Change from Baseline WHR at week 24
Primary Body Fat Percentage changes Body Fat Percentage changes measured in percentage Change from Baseline Body Fat Percentage at week 12
Primary Body Fat Percentage changes Body Fat Percentage changes measured in percentage Change from Baseline Body Fat Percentage at week 24
Primary Body Fat Mass changes Body Fat Mass changes measured in kilograms Change from Baseline Body Fat Mass at week 12
Primary Body Fat Mass changes Body Fat Mass changes measured in kilograms Change from Baseline Body Fat Mass at week 24
Primary Fat Free Mass changes Fat Free Mass changes measured in kilograms Change from Baseline Body Fat Mass at week 12
Primary Fat Free Mass changes Fat Free Mass changes measured in kilograms Change from Baseline Body Fat Mass at week 24
Primary Systolic Blood Pressure changes Systolic Blood Pressure changes measured in mmHg Change from Baseline Systolic Blood Pressure at week 12
Primary Systolic Blood Pressure changes Systolic Blood Pressure changes measured in mmHg Change from Baseline Systolic Blood Pressure at week 24
Primary Diastolic Blood Pressure changes Diastolic Blood Pressure changes measured in mmHg Change from Baseline Diastolic Blood Pressure at week 12
Primary Diastolic Blood Pressure changes Diastolic Blood Pressure changes measured in mmHg Change from Baseline Diastolic Blood Pressure at week 24
Primary Fasting Blood Glucose changes Fasting Blood Glucose changes measured in mmol/L Change from Baseline Fasting Blood Glucose at week 12
Primary Fasting Blood Glucose changes Fasting Blood Glucose changes measured in mmol/L Change from Baseline Fasting Blood Glucose at week 24
Primary 2-hour Post Prandial Blood Glucose changes 2-hour Post Prandial changes measured in mmol/L Change from Baseline 2-hour Post Prandial at week 12
Primary 2-hour Post Prandial Blood Glucose changes 2-hour Post Prandial changes measured in mmol/L Change from Baseline 2-hour Post Prandial at week 24
Primary HbA1c changes HbA1c changes measured in percentage Change from Baseline HbA1c at week 12
Primary HbA1c changes HbA1c changes measured in percentage Change from Baseline HbA1c at week 24
Primary Fasting Total Cholesterol changes Fasting Total Cholesterol changes measured in mmol/L Change from Baseline Fasting Total Cholesterol at week 12
Primary Fasting Total Cholesterol changes Fasting Total Cholesterol changes measured in mmol/L Change from Baseline Fasting Total Cholesterol at week 24
Primary Fasting Triglyceride changes Fasting Triglyceride changes measured in mmol/L Change from Baseline Fasting Triglyceride at week 12
Primary Fasting Triglyceride changes Fasting Triglyceride changes measured in mmol/L Change from Baseline Fasting Triglyceride at week 24
Primary Fasting High-density Lipoprotein-Cholesterol (HDL-C) changes Fasting HDL-C measured in mmol/L Change from Baseline Fasting HDL-C at week 12
Primary Fasting High-density Lipoprotein-Cholesterol (HDL-C) changes Fasting HDL-C measured in mmol/L Change from Baseline Fasting HDL-C at week 24
Primary Fasting Low-density Lipoprotein-Cholesterol (LDL-C) changes Fasting LDL-C measured in mmol/L Change from Baseline Fasting LDL-C at week 12
Primary Fasting Low-density Lipoprotein-Cholesterol (LDL-C) changes Fasting LDL-C measured in mmol/L Change from Baseline Fasting LDL-C at week 24
Primary Fasting Insulin changes Fasting Insulin measured in uU/ml Change from Baseline Fasting Insulin at week 12
Primary Fasting Insulin changes Fasting Insulin measured in uU/ml Change from Baseline Fasting Insulin at week 24
Secondary Quality of Life changes Quality of Life score measured by Obesity and Weight-Loss Quality of Life (OWLQOL ) questionnaire At baseline, week 12 and week 24
Secondary Dietary Intake changes Dietary intake changes measured by Food Frequency Questionnaire (FFQ) At baseline, week 12 and week 24
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2